Back to Search
Start Over
DNA damage response- and JAK-dependent regulation of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells exposed to 5-fluorouracil (5-FU)
- Source :
- Translational Oncology, Translational Oncology, Elsevier, 2021, 14 (8), pp.101110. ⟨10.1016/j.tranon.2021.101110⟩, Translational Oncology, 2021, 14 (8), pp.101110. ⟨10.1016/j.tranon.2021.101110⟩, Translational Oncology, Vol 14, Iss 8, Pp 101110-(2021)
- Publication Year :
- 2021
- Publisher :
- HAL CCSD, 2021.
-
Abstract
- Highlights • PD-L1 is an important immune checkpoint molecule expressed by HNSCC. • 5-FU induces PD-L1 expression in HNSCC cells. • PD-L1 upregulation is DNA damage Response- and JAK-dependent. • 5-FU potentiates the effect of the inflammatory cytokine Ifn-γ. • Targeting EGFR with cetuximab blunts PD-L1 expression induced by 5-FU.<br />Objectives The immune checkpoint molecule PD-L1 (CD274) is a crucial regulator of the tumor immune response. Its expression has been reported in the therapeutic context in Head and Neck Squamous Cell Carcinoma (HNSCC), but it remains unclear how therapeutically approved molecules regulate PD-L1 expression in HNSCC cells. Materials and methods Three HNSCC cell lines (BICR6, PE/CA-PJ34 and PE/CA-PJ41) were used to analyze PD-L1 expression by immunoblotting, immunofluorescence and QPCR. Freely-available single cell RNAseq data from HNSCC were also used. Results 5-Fluorouracil (5-FU) increased the expression of PD-L1 with high efficacy in HNSCC cells. Single cell RNAseq data suggested the specificity of the regulation of PD-L1 in this context. The effect of 5-FU on PD-L1 expression was related to its genotoxic effect and was prevented by extracellular application of thymidine or using a chemical inhibitor of the DNA damage Response kinases ATM/ATR. We found that the effect of 5-FU was additive or synergistic with IFN-γ, the canonical inducer of PD-L1 in epithelial cells. QPCR analysis confirmed this finding and identified JAK-dependent transcriptional activation of PD-L1/CD274 as the underlying mechanism. The induction of PD-L1 by 5-FU was partially prevented by Epidermal Growth Factor Receptor (EGFR) inhibition with cetuximab. Conclusion Our study highlights the specific DNA Damage Response- and JAK- dependent induction of PD-L1 by 5-FU in HNSCC cells. This induction is regulated by the cytokine context and is potentially therapeutically actionable.
- Subjects :
- 0301 basic medicine
PD-L1
Cancer Research
FDR, false discovery rate
DNA damage
medicine.medical_treatment
5-Fluorouracil
[SDV]Life Sciences [q-bio]
Cell
HNSCC, head and neck squamous cell carcinoma
head and neck squamous cell carcinoma
03 medical and health sciences
Interferon-gamma
0302 clinical medicine
R/M, Recurrent/Metastatic
DEG, differentially expressed genes
GO, Gene Ontology
medicine
Epidermal growth factor receptor
neoplasms
ICB, immune checkpoint blockers
RC254-282
Original Research
Cetuximab
biology
Chemistry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
IFN-γ, Interferon-γ
Head and neck squamous-cell carcinoma
Immune checkpoint
NGF, Nerve Growth Factor
3. Good health
JAK
[SDV] Life Sciences [q-bio]
030104 developmental biology
Cytokine
medicine.anatomical_structure
Oncology
Cell culture
030220 oncology & carcinogenesis
Cancer research
biology.protein
EGFR, Epidermal Growth Factor Receptor
TS, Thymidylate synthase
PD-L1, Programmed cell Death 1-Ligand 1
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 19447124 and 19365233
- Database :
- OpenAIRE
- Journal :
- Translational Oncology, Translational Oncology, Elsevier, 2021, 14 (8), pp.101110. ⟨10.1016/j.tranon.2021.101110⟩, Translational Oncology, 2021, 14 (8), pp.101110. ⟨10.1016/j.tranon.2021.101110⟩, Translational Oncology, Vol 14, Iss 8, Pp 101110-(2021)
- Accession number :
- edsair.doi.dedup.....db9adfddec84ee15f59ece028939f56d
- Full Text :
- https://doi.org/10.1016/j.tranon.2021.101110⟩